Motto of the day
Peter Mere Latham
Publishing house: International Journal of Hyperthermia
Main author: Yoko Harima
Other authors: K. Nagata, K. Harima, V. V. Ostapenko, Y. Tanaka, S. Sawada
Publication class: Clinical study
Phase: No data
Number of patients: 40
HT type: LRHT Capacitive
Description of HT type: Local HT, deep, capacitive
Device: Thermotron RF-8
Disease entity: Locally advanced cervical cancer
Symbol of disease entity: LACC
Types of combination with HT: HT+RT
CT type: N/A
Abstract. Background: To clarify the role of thermoradiotherapy for FIGO Stage IIIB cervical carcinomas, both the clinical response and survival of patients treated with radio- or thermoradiotherapy were investigated.
Methods: Forty patients with Stage IIIB uterine cervix carcinoma were treated with external beam irradiation to the pelvis, combined with iridium 192 high-dose-rate intracavitary brachytherapy. All patients were divided randomly into the following two groups: the radiotherapy (RT) group of 20 patients, who underwent radiotherapy alone; and the thermoradiotherapy (TRT) group of 20 patients, who underwent three sessions of hyperthermia in addition to radiotherapy.
Findings: The primary endpoint of this study was local complete response and survival. A complete response was achieved in 50% (10 of 20) in the RT group versus 80% (16 of 20) in the TRT group ( p ˆ 0:048). The 3-year overall survival and disease-free survival of the patients who were treated with TRT (58.2 and 63.6%) were better than those of the patients treated with RT (48.1 and 45%), but these diOEerences were not significant. The 3-year local relapse-free survival of the patients who were treated with TRT (79.7%) was significantly better than that of the patients treated with RT (48.5%) ( p ˆ 0:048). TRT, as delivered in this trial, as well tolerated and did not significantly add to either the relevant clinical acute or long-term toxicity over radiation alone.
Interpretation: TRT resulted in a better treatment response and 3-year local relapse-free survival rate than RT for patients with FIGO Stage IIIB cervical carcinoma..
Need more information about the article? Please contact with PTHO by email.